[go: up one dir, main page]

IL133316A0 - Ntn-2 member of tnf ligand family - Google Patents

Ntn-2 member of tnf ligand family

Info

Publication number
IL133316A0
IL133316A0 IL13331698A IL13331698A IL133316A0 IL 133316 A0 IL133316 A0 IL 133316A0 IL 13331698 A IL13331698 A IL 13331698A IL 13331698 A IL13331698 A IL 13331698A IL 133316 A0 IL133316 A0 IL 133316A0
Authority
IL
Israel
Prior art keywords
ntn
tnf ligand
ligand family
family
tnf
Prior art date
Application number
IL13331698A
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL133316A0 publication Critical patent/IL133316A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13331698A 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family IL133316A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4877697P 1997-06-06 1997-06-06
US6638797P 1997-11-21 1997-11-21
PCT/US1998/011294 WO1998055621A1 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Publications (1)

Publication Number Publication Date
IL133316A0 true IL133316A0 (en) 2001-04-30

Family

ID=26726521

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13331698A IL133316A0 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Country Status (6)

Country Link
EP (1) EP0991759A1 (en)
JP (1) JP2002517977A (en)
AU (1) AU7608898A (en)
CA (2) CA2292899A1 (en)
IL (1) IL133316A0 (en)
WO (1) WO1998055621A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP2002503444A (en) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー Ligand family genes
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU1467000A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
EP1354598A3 (en) * 1999-01-07 2003-11-19 ZymoGenetics, Inc. Therapeutic uses of BR43X2 soluble receptors
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000047740A2 (en) * 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
GEP20053685B (en) 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
KR20120053525A (en) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
SK288175B6 (en) 2001-05-11 2014-04-02 Amgen Inc. Peptides and related molecules that bind to TALL-1
ATE446771T1 (en) 2001-05-24 2009-11-15 Zymogenetics Inc TACI-IMMUNOGLOBULIN FUSION PROTEINS
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
WO2006044582A2 (en) * 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
AR059025A1 (en) 2005-08-09 2008-03-12 Zymogenetics Inc METHODS FOR THE TREATMENT AND PREVENTION OF PROLIFERATION OF ABNORMAL CELLS USING TACI FUSION MOLECULES
UA93516C2 (en) 2005-08-09 2011-02-25 Займоджинетикс, Инк. Methods for treating b-cell malignancies using taci-ig fusion molecule
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AR060935A1 (en) 2006-05-15 2008-07-23 Ares Trading Sa METHODS TO TREAT AUTOIMMUNE DISEASES USING A TACI-IG FUSION MOLECULA
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN106367714A (en) 2015-07-24 2017-02-01 先健科技(深圳)有限公司 Iron-based absorbent implanting medical instrument, prefabricated tube, and production methods of medical instrument and prefabricated tube
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665133A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents

Also Published As

Publication number Publication date
AU7608898A (en) 1998-12-21
CA2292835A1 (en) 1998-12-10
JP2002517977A (en) 2002-06-18
EP0991759A1 (en) 2000-04-12
CA2292899A1 (en) 1998-12-10
WO1998055621A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
IL133315A0 (en) Ntn-2 member of tnf ligand family
IL133316A0 (en) Ntn-2 member of tnf ligand family
GB2300015B (en) Downhole mixer
ZA982478B (en) Compounds their use and preparation
EP1033994A4 (en) Methods of preparation of bioginkgo
AU133473S (en) Lavatory
AU1700999A (en) Tnf ligand family gene
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
GB2323652B (en) Means of assembly
IL120979A0 (en) Glycosylated TNF
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
GB2329384B (en) Preparation of 1-chloro-1-cyclopropylethene
TW377910U (en) Combination of multiple-contacts connector
GB2286644B (en) Concealed connection of assembled elements
GB9700772D0 (en) Ramps
TW319017U (en) Improved structure of mousetraps
TW312301U (en) Improved structure of earmask
PL327430A1 (en) Set of shaped components
AU1466599A (en) Tnf ligand family gene
TW317151U (en) Structure of tea-making utensils
TW353924U (en) Improvement of blender
TW316466U (en) Structure of hangtag
TW314733U (en) Structure of hairclip
TW323470U (en) Structure of assembled simple hairclip
TW357554U (en) Improvement of shinguards